[Shanghai Securities News / China Securities Journal] InventisBio released its latest institutional survey minutes on January 29. The company recently hosted representatives from various domestic and international institutional investors, including Harvest Fund, Bank of Shanghai Fund, UBS, and IKARIA. Discussions centered on the R&D progress of the company’s product pipeline.

D-2570 Clinical Progress:
InventisBio stated that D-2570 is currently in clinical development for immunological diseases such as psoriasis, ulcerative colitis (UC), psoriatic arthritis, and systemic lupus erythematosus (SLE). In December 2025, Phase II clinical data for D-2570 in treating moderate-to-severe plaque psoriasis demonstrated excellent efficacy, significantly outperforming the placebo group across all endpoints after 12 weeks. Notably, significant improvements in lesion severity and area were observed after only 4 weeks, indicating that D-2570 can rapidly alleviate disease burden.

Garsorasib (D-1553) Updates:
A randomized, controlled, double-blind, multicenter Phase III clinical trial is currently underway, comparing Garsorasib with docetaxel in patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who failed standard therapy. Additionally, Garsorasib showed promising anti-tumor efficacy and a manageable safety profile in patients with advanced pancreatic cancer harboring KRAS G12C mutations. These findings were published in December 2025 in the British Journal of Cancer (BJC) (IF: 6.7).

D-0502 R&D Progress:
In December 2025, a combination therapy of D-0502 and Alphamab Oncology’s JSKN016 (a bispecific ADC targeting TROP2/HER3) received IND approval from the NMPA for locally advanced or metastatic HR+/HER2- breast cancer. This marks the first clinical exploration of D-0502 in combination with an ADC, aiming to provide a potential new treatment option for patients who have progressed on endocrine-based combinations.

D-0120, YF087, and YF550 Progress:
A Phase II clinical trial for D-0120 in combination with allopurinol was initiated in the U.S. in April 2023 and is progressing as planned. Meanwhile, YF087 and YF550 have demonstrated superior anti-tumor growth efficacy in multiple animal models; these preclinical results will provide robust support for subsequent clinical development.